1997
DOI: 10.1056/nejm199710093371503
|View full text |Cite
|
Sign up to set email alerts
|

Posteroventral Medial Pallidotomy in Advanced Parkinson's Disease

Abstract: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability. Much of the benefit is sustained at two years, although some improvements, such as those on the ipsilateral side and in axial symptoms, wane within the first year. The on-period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

25
268
2
7

Year Published

1998
1998
2007
2007

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 422 publications
(302 citation statements)
references
References 20 publications
25
268
2
7
Order By: Relevance
“…Side effects were rather mild in our sample, although only the Mini-Mental Status Examination and the confrontation method of testing visual fields were performed to detect the abnormalities reported with pallidotomies 4,[30][31][32][33][34] . The only patient with dysarthric speech was already with that deficit before the procedure (Case 2).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Side effects were rather mild in our sample, although only the Mini-Mental Status Examination and the confrontation method of testing visual fields were performed to detect the abnormalities reported with pallidotomies 4,[30][31][32][33][34] . The only patient with dysarthric speech was already with that deficit before the procedure (Case 2).…”
Section: Discussionmentioning
confidence: 99%
“…The growing experience with pallidal lesions for Parkinson's disease shows frequent improvement of all kind of dyskinesias/dystonias, including the ones not related to L-Dopa therapy [3][4][5][6][7][8][9][10][11] . These findings, along with some recent reports of marked improvement in medically refractory dystonias prompted us to evaluate the effectiveness of this procedure in a group of selected patients [12][13][14][15][16] .…”
mentioning
confidence: 99%
“…The reports of the pre-levodopa era [2][3][4] used nonvalidated methods of assessment, and those patients presented a different clinical profile when compared to the patients of the levodopa era. More recent studies [5][6][7][8][9][10][11][12][13][14][15][16] present different methods of assessment, leading to different conclusions.…”
mentioning
confidence: 99%
“…Firing pattern changes in the subthalamic nucleus (STN) and the basal ganglia output nuclei, the internal segment of the globus pallidus (GPi) and substantia nigra pars reticulata (SNpr), appear especially relevant to PD symptomatology. This is evidenced by the efficacy of STN and GPi lesion and deep brain stimulation treatments in advanced PD, procedures that eliminate or modify STN and GPi output (Baron et al, 1996;Gill and Heywood, 1997;Lang et al, 1997;Limousin et al, 1998;Krack et al, 2000;Lozano, 2001;Obeso et al, 2001;Benabid, 2003).The symptomatological relief associated with these therapies supports the idea that dopamine cell death triggers alterations in STN and GPi/SNpr activity that exert dysfunctional effects on downstream nuclei and contribute to the disabilities of PD.Animal models of PD provide an opportunity to explore the effect of dopamine cell loss on firing patterns in individual basal ganglia nuclei. In addition, they provide an opportunity to examine relationships between interconnected nuclei to gain insight into the extent to which firing pattern changes in individual nuclei are linked to broader changes engaging the entire basal ganglia network.…”
mentioning
confidence: 99%